Literature DB >> 33585000

Personalized medicine in colorectal cancer.

Padina Vaseghi Maghvan1, Shabnam Jeibouei2, Mohammad Esmael Akbari3, Vahid Niazi4, Farshid Karami4, Alireza Rezvani5, Nafiseh Ansarinejad6, Masroor Abbasinia7, Gisoo Sarvari8, Hakimeh Zali1,4, Ramin Talaie9.   

Abstract

Colorectal cancer (CRC) is a heterogeneous disease with various genetic and epigenetic factors leading to difficulties in response to both the therapy and drug resistance. Moreover, even in tumors with similar histopathological characteristics, different responses and molecular features could be observed because of the genetic basis and its interactions with the living environment. Through personalized medicine, we can classify patients into separate groups according to their genetic and epigenetic features and their susceptibility for a specific disease which could help with choosing the best therapeutic approach. In this review, genetic and epigenetic factors that cause heterogeneity in colorectal cancer are evaluated and proper drug administration in both chemotherapy and target therapy are suggested. ©2020 RIGLD, Research Institute for Gastroenterology and Liver Diseases.

Entities:  

Keywords:  Biomarker; Chemotherapy; Colorectal cancer; Personalized medicine; Targeted therapy

Year:  2020        PMID: 33585000      PMCID: PMC7881405     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol Bed Bench        ISSN: 2008-2258


  64 in total

1.  Abdominal pain due to lead-contaminated opium: a new source of inorganic lead poisoning in Iran.

Authors:  Mohsen Masoodi; Mohammad-Reza Zali; Mohammad-Javad Ehsani-Ardakani; Amir-Hoshang Mohammad-Alizadeh; Kazem Aiassofi; Rahim Aghazadeh; Ahmad Shavakhi; Mohammad-Hossein Somi; Mohammad-Hossein Antikchi; Saeed Yazdani
Journal:  Arch Iran Med       Date:  2006-01       Impact factor: 1.354

2.  Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature.

Authors:  Mercedes Herrera; Abul B M M K Islam; Alberto Herrera; Paloma Martín; Vanesa García; Javier Silva; Jose M Garcia; Clara Salas; Ignacio Casal; Antonio García de Herreros; Félix Bonilla; Cristina Peña
Journal:  Clin Cancer Res       Date:  2013-09-19       Impact factor: 12.531

Review 3.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.

Authors:  George Pentheroudakis; Leonidas Mavroeidis; Kyriaki Papadopoulou; Georgia-Angeliki Koliou; Christina Bamia; Kyriakos Chatzopoulos; Epaminontas Samantas; Davide Mauri; Ioannis Efstratiou; Dimitrios Pectasides; Thomas Makatsoris; Dimitrios Bafaloukos; Pavlos Papakostas; George Papatsibas; Iliada Bombolaki; Sofia Chrisafi; Helen P Kourea; Kalliopi Petraki; Georgia Kafiri; George Fountzilas; Vassiliki Kotoula
Journal:  Clin Colorectal Cancer       Date:  2019-07-15       Impact factor: 4.481

Review 5.  Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.

Authors:  Robert J Gillies; Daniel Verduzco; Robert A Gatenby
Journal:  Nat Rev Cancer       Date:  2012-06-14       Impact factor: 60.716

6.  Wnt activity defines colon cancer stem cells and is regulated by the microenvironment.

Authors:  Louis Vermeulen; Felipe De Sousa E Melo; Maartje van der Heijden; Kate Cameron; Joan H de Jong; Tijana Borovski; Jurriaan B Tuynman; Matilde Todaro; Christian Merz; Hans Rodermond; Martin R Sprick; Kristel Kemper; Dick J Richel; Giorgio Stassi; Jan Paul Medema
Journal:  Nat Cell Biol       Date:  2010-04-25       Impact factor: 28.824

7.  Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells.

Authors:  Giovanna Mirone; Stefania Perna; Arvind Shukla; Gabriella Marfe
Journal:  J Cell Physiol       Date:  2015-10-08       Impact factor: 6.384

Review 8.  Initial steps of metastasis: cell invasion and endothelial transmigration.

Authors:  Franziska van Zijl; Georg Krupitza; Wolfgang Mikulits
Journal:  Mutat Res       Date:  2011-05-12       Impact factor: 2.433

9.  HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.

Authors:  Susan D Richman; Katie Southward; Philip Chambers; Debra Cross; Jennifer Barrett; Gemma Hemmings; Morag Taylor; Henry Wood; Gordon Hutchins; Joseph M Foster; Assa Oumie; Karen G Spink; Sarah R Brown; Marc Jones; David Kerr; Kelly Handley; Richard Gray; Matthew Seymour; Philip Quirke
Journal:  J Pathol       Date:  2016-01-29       Impact factor: 7.996

Review 10.  Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review).

Authors:  Taxiarchis Konstantinos Nikolouzakis; Loukia Vassilopoulou; Persefoni Fragkiadaki; Theodoros Mariolis Sapsakos; Georgios Z Papadakis; Demetrios A Spandidos; Aristides M Tsatsakis; John Tsiaoussis
Journal:  Oncol Rep       Date:  2018-03-21       Impact factor: 4.136

View more
  1 in total

1.  Secretin Receptor as a Target in Gastrointestinal Cancer: Expression Analysis and Ligand Development.

Authors:  Anja Klussmeier; Stefan Aurich; Lars Niederstadt; Bertram Wiedenmann; Carsten Grötzinger
Journal:  Biomedicines       Date:  2022-02-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.